Summary
Global Markets Direct’s, ‘Low Back Pain - Pipeline Review, H1 2016’, provides an overview of the Low Back Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Low Back Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Low Back Pain
- The report reviews pipeline therapeutics for Low Back Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Low Back Pain therapeutics and enlists all their major and minor projects
- The report assesses Low Back Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Low Back Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Low Back Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adynxx, Inc.
Aestus Therapeutics, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Axsome Therapeutics, Inc.
Egalet Corporation
Frontier Biotechnologies Co., Ltd
Gador S.A.
Grunenthal GmbH
Hisamitsu Pharmaceutical Co., Inc.
Immune Pharmaceuticals Inc.
Kineta, Inc.
MEDRx Co., Ltd.
Mesoblast Limited
Nektar Therapeutics
Orion Oyj
Pacira Pharmaceuticals, Inc.
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Stayble Therapeutics AB
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Low Back Pain Overview 9
Therapeutics Development 10
Pipeline Products for Low Back Pain - Overview 10
Low Back Pain - Therapeutics under Development by Companies 11
Low Back Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Low Back Pain - Products under Development by Companies 16
Low Back Pain - Companies Involved in Therapeutics Development 17
Adynxx, Inc. 17
Aestus Therapeutics, Inc. 18
Array BioPharma Inc. 19
Astellas Pharma Inc. 20
Axsome Therapeutics, Inc. 21
Egalet Corporation 22
Frontier Biotechnologies Co., Ltd 23
Gador S.A. 24
Grunenthal GmbH 25
Hisamitsu Pharmaceutical Co., Inc. 26
Immune Pharmaceuticals Inc. 27
Kineta, Inc. 28
MEDRx Co., Ltd. 29
Mesoblast Limited 30
Nektar Therapeutics 31
Orion Oyj 32
Pacira Pharmaceuticals, Inc. 33
Pfizer Inc. 34
Regeneron Pharmaceuticals, Inc. 35
Stayble Therapeutics AB 36
Low Back Pain - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(etodolac + lidocaine) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(naltrexone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AB-001 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ARRY-954 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ASP-7962 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ATX-09002 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AYX-2 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
bupivacaine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cebranopadol - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
dexmedetomidine hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drug for Chronic Low Back Pain - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
fasinumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
HP-3150 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IG-8801 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lidocaine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MPC-06ID - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NKTR-181 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
oxycodone hydrochloride ER - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
tanezumab - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
U-2902 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
zoledronic acid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Low Back Pain - Recent Pipeline Updates 82
Low Back Pain - Dormant Projects 97
Low Back Pain - Discontinued Products 99
Low Back Pain - Product Development Milestones 100
Featured News & Press Releases 100
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 100
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 100
Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104
List of Tables
Number of Products under Development for Low Back Pain, H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Low Back Pain - Pipeline by Adynxx, Inc., H1 2016 17
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H1 2016 18
Low Back Pain - Pipeline by Array BioPharma Inc., H1 2016 19
Low Back Pain - Pipeline by Astellas Pharma Inc., H1 2016 20
Low Back Pain - Pipeline by Axsome Therapeutics, Inc., H1 2016 21
Low Back Pain - Pipeline by Egalet Corporation, H1 2016 22
Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016 23
Low Back Pain - Pipeline by Gador S.A., H1 2016 24
Low Back Pain - Pipeline by Grunenthal GmbH, H1 2016 25
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 26
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc., H1 2016 27
Low Back Pain - Pipeline by Kineta, Inc., H1 2016 28
Low Back Pain - Pipeline by MEDRx Co., Ltd., H1 2016 29
Low Back Pain - Pipeline by Mesoblast Limited, H1 2016 30
Low Back Pain - Pipeline by Nektar Therapeutics, H1 2016 31
Low Back Pain - Pipeline by Orion Oyj, H1 2016 32
Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2016 33
Low Back Pain - Pipeline by Pfizer Inc., H1 2016 34
Low Back Pain - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 35
Low Back Pain - Pipeline by Stayble Therapeutics AB, H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Assessment by Combination Products, H1 2016 38
Number of Products by Stage and Target, H1 2016 40
Number of Products by Stage and Mechanism of Action, H1 2016 42
Number of Products by Stage and Route of Administration, H1 2016 44
Number of Products by Stage and Molecule Type, H1 2016 46
Low Back Pain Therapeutics - Recent Pipeline Updates, H1 2016 82
Low Back Pain - Dormant Projects, H1 2016 97
Low Back Pain - Dormant Projects (Contd..1), H1 2016 98
Low Back Pain - Discontinued Products, H1 2016 99
List of Figures
Number of Products under Development for Low Back Pain, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 37
Assessment by Combination Products, H1 2016 38
Number of Products by Top 10 Targets, H1 2016 39
Number of Products by Stage and Top 10 Targets, H1 2016 39
Number of Products by Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Top 10 Routes of Administration, H1 2016 43
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 43
Number of Products by Molecule Types, H1 2016 45
Number of Products by Stage and Molecule Types, H1 2016 45
